Tiuri Kroese, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses the need for a randomised or prospective trial investigating the best treatments for patients with oligometastatic esophagogastric cancer, to build upon the results of the recent retropspective trial which determined that local therapy plus systemic therapy resulted in the best overall and progression-free survival for these patients. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.